English | Español

Amgen Inc.
Press release submission | Dec 20, 2021

FDA Approves Otezla® (Apremilast) for the Treatment of Adult Patients With Plaque Psoriasis, Regardless of Severity Level

Press release submission | Sep 5, 2021

New Tezepelumab Data Show 86% Reduction In Exacerbations In Patients With Severe Asthma And Comorbid Nasal Polyps
Press release submission | Mar 15, 2019

AMGEN, INC.: Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke
Carol Ostrow | Dec 15, 2017

Amgen Foundation commits $500,000 to help southern California wildfire victims
Carol Ostrow | Dec 10, 2017

Amgen's Repatha wins FDA approval
Carol Ostrow | Dec 8, 2017

Amgen presents at Evercore conference
Mark Iandolo | Nov 1, 2017

Cancer information awareness campaign features conversations with Joan Lunden
Kathy Adams | Oct 22, 2017

Amgen, Boston Children's Hospital team up for study on unusual pain response

Trending
Patient Daily | Aug 18, 2025

Medfluence Advisors’ Greg Caesar to open ASCENT 2025 with keynote on digital practice growth
+ Pharmaceuticals
Patient Daily | Aug 18, 2025

Patients Come First spokesperson on 340B rebate model: ‘This rebate model provides the oversight that 340B has needed for decades’
Patient Daily | Aug 21, 2025

SoCal Breathe Free doctor on balloon sinuplasty: ‘The procedure itself is pretty quick and effectiveness is pretty high’
+ Pharmaceuticals
Patient Daily | Aug 21, 2025

PhRMA director of public affairs on 340B rebate model: "Positive first step toward addressing hospital abuse of the 340B program